Published :
Tables : 44
Figures : 44
Category : Healthcare
No. of Pages : 232
Report Code : HC-U3730
Neuromodulation Market is poised to value USD 11627.20 million by 2028 end at a CAGR of 11.8% during the forecast period 2022 to 2028. FutureWise Market Research has instantiated a report that provides an intricate analysis of Neuromodulation Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Neuromodulation Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Neuromodulation Market: • Medtronic plc • Boston Scientific Corporation • Abbott • Livanova • Nevro Corporation • Neurosigma, Inc. • Neuropace, Inc. • Biocontrol Medical • Synapse Biomedical • Neuronetics • Bioness • Soterix Medical • Bioinduction • Integer Holdings Corporation • Gimer Medical • GTX Medical • Helius Medical Technologies • Microtransponder • Neuronano • Bluewind Medical (Note: The list of the major players will be updated with the latest market scenario and trends) Neuromodulation Market Segmentation: By Technology • Internal Neuromodulation o Spinal Cord Stimulation o Deep Brain Stimulation o Vagus Nerve Stimulation o Sacral Nerve Stimulation o Gastric Electrical Stimulation • External Neuromodulation o Transcutaneous Electrical Nerve Stimulation (TENS) o Transcranial Magnetic Stimulation (TMS) o Respiratory Electrical Stimulation (RES) By Application • Spinal Cord Stimulation o Chronic Pain o Failed Back Surgery Syndrome o Ischemia • Deep Brain Stimulation o Parkinson’s Disease o Tremors o Depression o Other DBS Applications • Sacral Nerve Stimulation Market o Urinary Incontinence o Fecal Incontinence • Vagus Nerve Stimulation o Epilepsy o Other Vns Applications • Gastric Electrical Stimulation o Gastroparesis o Obesity • Transcutaneous Electrical Nerve Stimulation o Treatment-Resistant Depression o Other Tens Applications • Transcranial Magnetic Stimulation o Depression o Migraine • Respiratory Electrical Stimulation o Spinal Cord Injury By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Neuromodulation Market By Technology, By Application and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Technology launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Neuromodulation Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Neuromodulation Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Neuromodulation Market: • Medtronic plc • Boston Scientific Corporation • Abbott • Livanova • Nevro Corporation • Neurosigma, Inc. • Neuropace, Inc. • Biocontrol Medical • Synapse Biomedical • Neuronetics • Bioness • Soterix Medical • Bioinduction • Integer Holdings Corporation • Gimer Medical • GTX Medical • Helius Medical Technologies • Microtransponder • Neuronano • Bluewind Medical (Note: The list of the major players will be updated with the latest market scenario and trends)
Neuromodulation Market Segmentation: By Technology • Internal Neuromodulation o Spinal Cord Stimulation o Deep Brain Stimulation o Vagus Nerve Stimulation o Sacral Nerve Stimulation o Gastric Electrical Stimulation • External Neuromodulation o Transcutaneous Electrical Nerve Stimulation (TENS) o Transcranial Magnetic Stimulation (TMS) o Respiratory Electrical Stimulation (RES) By Application • Spinal Cord Stimulation o Chronic Pain o Failed Back Surgery Syndrome o Ischemia • Deep Brain Stimulation o Parkinson’s Disease o Tremors o Depression o Other DBS Applications • Sacral Nerve Stimulation Market o Urinary Incontinence o Fecal Incontinence • Vagus Nerve Stimulation o Epilepsy o Other Vns Applications • Gastric Electrical Stimulation o Gastroparesis o Obesity • Transcutaneous Electrical Nerve Stimulation o Treatment-Resistant Depression o Other Tens Applications • Transcranial Magnetic Stimulation o Depression o Migraine • Respiratory Electrical Stimulation o Spinal Cord Injury By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Neuromodulation Market By Technology, By Application and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Technology launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Neuromodulation Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Neuromodulation Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Neuromodulation Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Neuromodulation Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Internal Neuromodulation 7.1.1. Spinal Cord Stimulation 7.1.2. Deep Brain Stimulation 7.1.3. Vagus Nerve Stimulation 7.1.4. Sacral Nerve Stimulation 7.1.5. Gastric Electrical Stimulation 7.2. External Neuromodulation 7.2.1. Transcutaneous Electrical Nerve Stimulation (TENS) 7.2.2. Transcranial Magnetic Stimulation (TMS) 7.2.3. Respiratory Electrical Stimulation (RES) 8. Neuromodulation Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Spinal Cord Stimulation 8.1.1. Failed Back Syndrome 8.1.2. Chronic Pain 8.1.3. Ischemia 8.2. Deep Brain Stimulation 8.2.1. Parkinson’s Disease 8.2.2. Tremor 8.2.3. Depression 8.2.4. Other DBS Applications 8.3. Sacral Nerve Stimulation 8.3.1. Urine Incontinence 8.3.2. Fecal Incontinence 8.4. Vagus Nerve Stimulation 8.4.1. Epilepsy 8.4.2. Other VNS Applications 8.5. Gastric Electrical Stimulation 8.5.1. Gastroparesis 8.5.2. Obesity 8.6. Transcutaneous Electrical Nerve Stimulation 8.6.1. Treatment-resistant Depression 8.6.2. Other TENS Applications 8.7. Transcranial Magnetic Stimulation 8.7.1. Depression 8.7.2. Migraine Headache 8.8. Respiratory Electrical Stimulation 8.8.1. Spinal Cord Injury 9. North America Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028 10. Latin America Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028 11. Europe Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028 12. Asia Pacific Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028 14. Market Share Analysis and Competitive Landscape 14.1. Global Landscape - Key Players, Revenue and Presence 14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 14.3. Global Emerging Companies 14.4. North America - Market Share Analysis and Key Regional Players 14.5. Europe - Market Share Analysis and Key Regional Players 14.6. Asia Pacific - Market Share Analysis and Key Regional Players 14.7. Global Key Player - Growth Matrix 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Technologys Offered and Financial Layouts) 15.1. Medtronic plc 15.1.1. Company Overview 15.1.2. Technology Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Boston Scientific Corporation 15.2.1. Company Overview 15.2.2. Technology Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Abbott 15.3.1. Company Overview 15.3.2. Technology Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Livanova. 15.4.1. Company Overview 15.4.2. Technology Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5. Nevro Corporation 15.5.1. Company Overview 15.5.2. Technology Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6. Neurosigma, Inc. 15.6.1. Company Overview 15.6.2. Technology Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Neuropace, Inc. 15.7.1. Company Overview 15.7.2. Technology Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Biocontrol Medical 15.8.1. Company Overview 15.8.2. Technology Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Synapse Biomedical 15.9.1. Company Overview 15.9.2. Technology Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10.Neuronetics 15.10.1. Company Overview 15.10.2. Technology Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11.Bioness 15.11.1. Company Overview 15.11.2. Technology Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12.Soterix Medical 15.12.1. Company Overview 15.12.2. Technology Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13.Integer Holdings Corporation 15.13.1. Company Overview 15.13.2. Technology Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14.Bioinduction 15.14.1. Company Overview 15.14.2. Technology Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 15.15.Gimer Medical 15.15.1. Company Overview 15.15.2. Technology Portfolio 15.15.3. SWOT Analysis 15.15.4. Financial Overview 15.15.5. Strategic Overview 15.16.GTX Medical 15.16.1. Company Overview 15.16.2. Technology Portfolio 15.16.3. SWOT Analysis 15.16.4. Financial Overview 15.16.5. Strategic Overview 15.17.Helius Medical Technologies 15.17.1. Company Overview 15.17.2. Technology Portfolio 15.17.3. SWOT Analysis 15.17.4. Financial Overview 15.17.5. Strategic Overview 15.18.Microtransponder 15.18.1. Company Overview 15.18.2. Technology Portfolio 15.18.3. SWOT Analysis 15.18.4. Financial Overview 15.18.5. Strategic Overview 15.19.Neuronano 15.19.1. Company Overview 15.19.2. Technology Portfolio 15.19.3. SWOT Analysis 15.19.4. Financial Overview 15.19.5. Strategic Overview 15.20.Bluewind Medical 15.20.1. Company Overview 15.20.2. Technology Portfolio 15.20.3. SWOT Analysis 15.20.4. Financial Overview 15.20.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Neuromodulation Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Neuromodulation Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Neuromodulation Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Neuromodulation Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Internal Neuromodulation 7.1.1. Spinal Cord Stimulation 7.1.2. Deep Brain Stimulation 7.1.3. Vagus Nerve Stimulation 7.1.4. Sacral Nerve Stimulation 7.1.5. Gastric Electrical Stimulation 7.2. External Neuromodulation 7.2.1. Transcutaneous Electrical Nerve Stimulation (TENS) 7.2.2. Transcranial Magnetic Stimulation (TMS) 7.2.3. Respiratory Electrical Stimulation (RES)
8. Neuromodulation Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Spinal Cord Stimulation 8.1.1. Failed Back Syndrome 8.1.2. Chronic Pain 8.1.3. Ischemia 8.2. Deep Brain Stimulation 8.2.1. Parkinson’s Disease 8.2.2. Tremor 8.2.3. Depression 8.2.4. Other DBS Applications 8.3. Sacral Nerve Stimulation 8.3.1. Urine Incontinence 8.3.2. Fecal Incontinence 8.4. Vagus Nerve Stimulation 8.4.1. Epilepsy 8.4.2. Other VNS Applications 8.5. Gastric Electrical Stimulation 8.5.1. Gastroparesis 8.5.2. Obesity 8.6. Transcutaneous Electrical Nerve Stimulation 8.6.1. Treatment-resistant Depression 8.6.2. Other TENS Applications 8.7. Transcranial Magnetic Stimulation 8.7.1. Depression 8.7.2. Migraine Headache 8.8. Respiratory Electrical Stimulation 8.8.1. Spinal Cord Injury
9. North America Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028
10. Latin America Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028
11. Europe Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028
12. Asia Pacific Neuromodulation Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028
14. Market Share Analysis and Competitive Landscape 14.1. Global Landscape - Key Players, Revenue and Presence 14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 14.3. Global Emerging Companies 14.4. North America - Market Share Analysis and Key Regional Players 14.5. Europe - Market Share Analysis and Key Regional Players 14.6. Asia Pacific - Market Share Analysis and Key Regional Players 14.7. Global Key Player - Growth Matrix
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Technologys Offered and Financial Layouts) 15.1. Medtronic plc 15.1.1. Company Overview 15.1.2. Technology Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Boston Scientific Corporation 15.2.1. Company Overview 15.2.2. Technology Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Abbott 15.3.1. Company Overview 15.3.2. Technology Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Livanova. 15.4.1. Company Overview 15.4.2. Technology Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5. Nevro Corporation 15.5.1. Company Overview 15.5.2. Technology Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6. Neurosigma, Inc. 15.6.1. Company Overview 15.6.2. Technology Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Neuropace, Inc. 15.7.1. Company Overview 15.7.2. Technology Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Biocontrol Medical 15.8.1. Company Overview 15.8.2. Technology Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Synapse Biomedical 15.9.1. Company Overview 15.9.2. Technology Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10.Neuronetics 15.10.1. Company Overview 15.10.2. Technology Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11.Bioness 15.11.1. Company Overview 15.11.2. Technology Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12.Soterix Medical 15.12.1. Company Overview 15.12.2. Technology Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13.Integer Holdings Corporation 15.13.1. Company Overview 15.13.2. Technology Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14.Bioinduction 15.14.1. Company Overview 15.14.2. Technology Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 15.15.Gimer Medical 15.15.1. Company Overview 15.15.2. Technology Portfolio 15.15.3. SWOT Analysis 15.15.4. Financial Overview 15.15.5. Strategic Overview 15.16.GTX Medical 15.16.1. Company Overview 15.16.2. Technology Portfolio 15.16.3. SWOT Analysis 15.16.4. Financial Overview 15.16.5. Strategic Overview 15.17.Helius Medical Technologies 15.17.1. Company Overview 15.17.2. Technology Portfolio 15.17.3. SWOT Analysis 15.17.4. Financial Overview 15.17.5. Strategic Overview 15.18.Microtransponder 15.18.1. Company Overview 15.18.2. Technology Portfolio 15.18.3. SWOT Analysis 15.18.4. Financial Overview 15.18.5. Strategic Overview 15.19.Neuronano 15.19.1. Company Overview 15.19.2. Technology Portfolio 15.19.3. SWOT Analysis 15.19.4. Financial Overview 15.19.5. Strategic Overview 15.20.Bluewind Medical 15.20.1. Company Overview 15.20.2. Technology Portfolio 15.20.3. SWOT Analysis 15.20.4. Financial Overview 15.20.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics